Citadel Made More Than $4 Billion From Commodities In 2023 (Bloomberg)
Pantera Capital Reveals $500 Billion Opportunity For Bitcoin (The Street)
Jeffrey Epstein Accuser Drops Lawsuit Against Wall St.
Keep Reading →
February 22 - Hedge Funds, Insider Trading
Crypto technology firm Lightning Labs said it is bringing in new financing as it creates a protocol to facilitate fiat currency transfers to Bitcoin.
Keep Reading →
April 5 - Hedge Funds, Insider Trading
Biotech companies are research science-driven companies focusing on novel drug development and clinical research with aims to treat diseases and medical conditions.
Keep Reading →
December 17 - ETF Trading, Hedge Funds, News, Tech
Hedge fund manager Ali Lumsden gained 73% the last time the mortgage-bond market went into meltdown. This time around, the veteran investor is on the wrong side of the crisis.
Keep Reading →
April 21 - Hedge Funds, Insider Trading
For Jim Simons, history is repeating itself, at least when it comes to meltdowns in the quant fund world.
Keep Reading →
April 17 - Hedge Funds, Insider Trading
Correction: A previous version of this article erroneously presented older events about the case between Sanofi/Regeneron and Amgen.
Keep Reading →
February 9 - News, Stock Analysis
Have you ever wondered which are the highest paid CEOs in the world? Companies in the corporate world are ready to push to the limits to compensate their CEOs, despite of the ...
Keep Reading →
January 30 - Lists, News
Thursday was a big day for two companies, in two very different ways, in the biotech space.
Keep Reading →
December 9 - News, Stock Analysis
The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (...
Keep Reading →
December 9 - News, Stock Analysis
Eylea has been one of the main drivers of growth for Regeneron over the past couple of years.
Keep Reading →
November 8 - News, Stock Analysis
It's another quiet day on the Street as the main indexes are moderately in the green while the VIX is down 3% to trade below 15.
Keep Reading →
October 28 - Market Movers, News
Bringing something new to the table is something that seems to be difficult these days, considering that many things have already been done, have already been invented, and have...
Keep Reading →
October 26 - Hedge Funds, Lists, News
In this article, we will analyze the latest events surrounding Amazon.com, Inc.
Keep Reading →
October 13 - News, Tech
Although much of the market's attention is on Twitter Inc (NYSE:TWTR) after various reports said that several ideal matches won't bid for the social media company, traders are...
Keep Reading →
October 6 - Market Movers, News
A number of companies have taken severe hits over the last week in the small cap biotech space, but a handful of these have had a particularly bad start to the final quarter of...
Keep Reading →
October 5 - Market Movers, News
The three major indexes are flat this morning as many traders look for a sense of market direction before jumping in.
Keep Reading →
October 4 - Earnings Report, Market Movers, News
Although the broader markets barely moved for the last week of the third quarter with the S&P 500 up around 0.14% and the Dow Jones 0.26% in green, shares of five companies, ...
Keep Reading →
October 2 - News, Tech
The major indexes opened higher on the last trading day of the quarter as some investors remain on the sidelines due to the Deutsche Bank uncertainty.
Keep Reading →
September 30 - News
OrbiMed Advisors LLC is the world’s largest healthcare-focused investment firm, managing roughly $15 billion in net assets under management.
Keep Reading →
April 1 - Hedge Funds, News
Sivik Global Healthcare is a Greenwich, Connecticut-based healthcare-focused hedge fund founded by Krishen Sud in 2006.
Keep Reading →
November 9 - Hedge Fund Analysis, Hedge Funds, News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has, once again, shown today why biopharmaceuticals companies are so popular with investors, especially those with a speculative...
Keep Reading →
October 17 - News
On Monday the stocks have been volatile with the S&P 500 INDEX (INDEXCBOE:SPX) edging down by 0.15% to 1,960.11 so far, and oscillating between 1,959.76 and 1,963.74, while...
Keep Reading →
June 23 - Market Movers, News
Orbimed Advisors is limiting exposure to Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after selling approximately 81,305 shares in one transaction at $320 a piece, according...
Keep Reading →
April 14 - Hedge Funds, News
Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.
Keep Reading →
March 6 - Hedge Funds, News
On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S.
Keep Reading →
January 29 - Insider Trading, News
More than anything, biotech companies need investors who are true believers in their products.
Keep Reading →
September 17 - News
French drugmaker Sanofi SA (ADR) (NYSE:SNY) counted that much money in its coffers as of the end of June, including cash, cash equivalents, and short-term investments.
Keep Reading →
September 17 - News
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 14 - News
The last several months have been remarkably exciting in the biotech space.
Keep Reading →
September 11 - News
Based on today's economic data, you would certainly have expected a more robust rally than what the broad-based S&P 500 (INDEXSP:.INX) ended up gaining, but beggars can't be...
Keep Reading →
September 4 - News
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
August 27 - News
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Keep Reading →
August 26 - News
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
At some point, a company reaches a level of maximum valuation. It doesn't mean the company becomes bad, but rather all upside is priced in and future gains are limited.
Keep Reading →
August 22 - News
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection.
Keep Reading →
August 12 - News
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.
Keep Reading →
August 12 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates.
Keep Reading →
August 9 - News
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Keep Reading →
August 8 - News
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug.
Keep Reading →
August 8 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 7 - News
Around four in 10 Americans live in places where smog can impact their health.
Keep Reading →
August 5 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will release its quarterly report on Tuesday, and the company's stock has been on an absolute tear over the past year.
Keep Reading →
August 2 - News
